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Received: 4 April 2016 / Revised: 10 May 2016 / Accepted: 10 May 2016
 Springer-Verlag Berlin Heidelberg 2016
Abstract Mutations in XPR1, a gene encoding an inor-
ganic phosphate exporter, have recently been identified in
patients with primary familial brain calcification (PFBC).
Using Sanger sequencing, we screened XPR1 in 18 unre-
lated patients with PFBC and no SLC20A2, PDGFB, or
PDGFRB mutation. XPR1 variants were tested in an
in vitro physiological complementation assay and patient
blood cells were assessed ex vivo for phosphate export. We
identified a novel c.260T[C, p.(Leu87Pro) XPR1 variant
in a 41-year-old man complaining of micrographia and
dysarthria and demonstrating mild parkinsonism, cerebellar
ataxia and executive dysfunction. Brain 123I-Ioflupane
scintigraphy showed marked dopaminergic neuron loss.
Peripheral blood cells from the patient exhibited decreased
phosphate export. XPR1 in which we introduced the
mutation was not detectable at the cell surface and did not
lead to phosphate export. These results confirm that loss of
XPR1-mediated phosphate export function causes PFBC,
occurring in less than 8 % of cases negative for the other
genes, and may be responsible for parkinsonism.
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1 Département de Neurologie, Hôpital de Hautepierre, CHU de
Strasbourg, Strasbourg, France
2 Institut de Génétique et de Biologie Moléculaire et Cellulaire
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5 Université de Montpellier, Cedex 5, 34293 Montpellier,
France
6 Laboratory of Excellence EpiGenMed, Montpellier, France
7 Laboratory of Excellence GR-Ex, Paris, France
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Introduction
Primary familial brain calcification (PFBC) is a rare con-
dition defined by calcification affecting at least both len-
ticular nuclei more severely than during uncomplicated
aging [1], with no cause identified following accurate eti-
ological assessment [2]. Calcification may also affect
caudate nuclei, thalami, dentate nuclei, cerebellum,
supratentorial white matter and cortical sulci. Clinical signs
associated with PFBC are numerous and optional. In a
French-Brazilian case series, 58 % patients exhibited at
least one neuropsychiatric sign [3], of which the most
frequent were psychiatric signs (76 % of symptomatic
patients), movement disorders (MD) (61 %) and cognitive
impairment (58 %), followed by speech, gait, cerebellar
syndrome, pyramidal signs, and seizures. Akinetic-hyper-
tonic syndrome, with or without tremor, was the most
common MD. Inheritance of PFBC is autosomal dominant.
Four causative genes have been identified: SLC20A2 [4],
PDGFRB [5], PDGFB [6] and, most recently, XPR1 [7].
SLC20A2 encodes PiT2, an inorganic phosphate importer
and we have recently shown that XPR1 [8] is the only
known human phosphate exporter [9, 10]. SLC20A2 loss of
function variants have been identified in a majority of cases
[11], and all 4 XPR1 missense variants identified in 5
unrelated families were located in the SPX putative regu-
latory domain of XPR1, causing significantly altered
XPR1-mediated phosphate export [7]. In this study, we
aimed at extending these recent clinical, molecular and
functional data by screening new patients and functional
characterization of the variants.
Methods
Patients
Patients were included following previously described
criteria [1]. Briefly, probands exhibited (1) at least bilateral
lenticular calcification, (2) a total calcification score (TCS)
above the age-specific threshold using our visual rating
scale [1], and (3) a negative etiological assessment.
The objective of the etiological assessment was to
search for other causes of brain calcification. For review
see Ref. [12]. The assessment was based on clinical
examination, brain MRI when available, and the exclusion
of causes of non-syndromic brain calcification by the fol-
lowing minimal biological assessment: Phosphate and
calcium levels in blood and urine, parathormone and
25-OH-vitamine D levels, and blood lactates and pyru-
vates. Depending on the clinical and MRI presentation,
other assessments may be required to look for other causes;
however, this was not the case for any of the patients
included in this study.
The patients gave written consent and local ethics
committee approved the study. All patients were nega-
tively screened for SLC20A2, PDGFB, and PDGFRB
variants by Sanger sequencing and Quantitative Multi-
plex PCR of Short Fluorescent fragments (QMPSF)
(SLC20A2, PDGFB). XPR1 sequencing was performed
by Sanger sequencing as previously described [7]. The
reference transcript NM_004736.3 was used for variant
nomenclature.
Functional analyses
Cells
HEK293T cells were cultured in DMEM supplemented
with 10 % FBS (PAN-Biotech) and non-essential amino
acids. Cells were incubated at 37 C in a 5 % CO2 and
humid atmosphere. For phosphate-free experiments, cells
were cultured in phosphate-free DMEM supplemented with
10 % dialyzed FBS [7, 10].
Plasmids and siRNAs
The c.260T[C, p.(Leu87Pro) mutation, thereafter refer-
red to as L87P, was generated by recombinant PCR site-
direct mutagenesis. The HA-tagged human wild type (WT)
and L87P XPR1 variant were introduced in the pCHIX [13]
and pLXSN-retroviral vectors [14]. Small interfering
RNAs (siRNA, Integrated DNA Technologies) targeting
the human XPR1 30UTR and the firefly luciferase gene
were described previously [10]). For the XPR1 comple-
mentation assay, HEK293T cells grown on poly-D-lysine-
coated 6-well plates were transfected with 50 pmol siRNA
per well using the calcium phosphate method along with
either empty or XPR1 expression vectors.
Phosphate fluxes
Phosphate uptake and efflux assays were performed in
HEK293T cells as previously described [10]. Percentage of
phosphate uptake was calculated as the ratio of cellular
[33P]phosphate to total [33P]phosphate supplemented. Per-
centage of phosphate efflux was calculated as the ratio of
released [33P]phosphate to total cellular [33P]phosphate.
Although synchronization was arduous, we were able to
perform phosphate efflux assays in peripheral blood
mononuclear cells (PBMC) from some patients as previ-
ously described [7].
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Immunoblotting
Cell extracts were separated by 12 % SDS-PAGE under
reducing conditions and transferred to PVDF membranes.
Protein expression and transfer were monitored with anti-
HA tag antibodies (3F10, Roche; 1:5000) or anti-b-actin
(A5441, Sigma-Aldrich; 1:5000), followed by horseradish
peroxidase (HRP)-conjugated anti-mouse or anti-rat anti-
bodies (Southern Biotech; 1:5000), and visualization with
Pierce ECL western blotting substrate (Thermo Scientific).
Flow cytometry
Cell surface expression of phosphate transporters was
monitored with soluble ligands derived from the receptor-
binding domain (RBD) of different retroviral envelope
glycoproteins. Production of and binding with RBD from
X-MLV (XRBD), and koala retrovirus (KoRBD), or with a
soluble ligand derived from the surface unit (SU) of
amphotropic-MLV (ASU), used to detect XPR1, PiT1, and
PiT2, respectively were performed as previously described
[10, 15]. Briefly, 5 9 105 cells were resuspended in PBA
(PBS with 2 % FBS) containing the adequate RBD and
incubated for 30 min at 37 C, followed by two washes
with PBA and incubation with an Alexa Fluor 488-conju-
gated anti-mouse IgG1 antibody (Life Technologies;
1:5000) for 20 min at 4 C. Cells were promptly analyzed
on FACSCalibur instrument (Becton–Dickinson) and data
were analyzed with the FlowJo package.
Statistical analysis
Student’s t test was applied using GraphPad Prism 6 soft-
ware; P values were as follows: *P B 0.05, **P B 0.01,
***P B 0.001, ****P B 0.0001.
Results
Eighteen patients with PFBC were included: 6 probands
with a pedigree suggestive of an autosomal dominant
inheritance and 12 sporadic cases. In one patient, we
identified a novel XPR1 missense variant, c.260T[C,
p.(Leu87Pro), thereafter referred as L87P, not reported in
exome databases, including the ExAC 60,706 exomes
(http://exac.broadinstitute.org/). The change, located on a
highly conserved residue, is predicted to affect protein
function by at least three programs (Mutation Taster, SIFT,
Polyphen2). DNA of relatives was not available. This
variant was absent from 126 French control exomes (not
shown).
The patient carrying the L87P variant is a right-handed
41-year-old man, with neither previous medical history nor
treatment. He was referred to our tertiary MD center
because he was complaining of insidious, slowly progres-
sive writing difficulties, slight dysarthria and concentration
deficiency for 10 years. His father experienced parkinson-
ism as well as dysarthria and concentration deficiency,
associated with calcification on CT scan before dying from
cancer at age 64. The patient’s paternal aunt was diagnosed
with Parkinson’s disease but subsequently lost to follow-up
(Fig. 1). Examination of the proband revealed mild dys-
arthria suggestive of both parkinsonism and cerebellar
dysfunction, micrography (which was not the case several
years before), mild hypermetria during the finger chase test
and mildly abnormal fast alternative hand movement.
There was mild rigidity of right wrist (1/4) but no tremor,
dystonia, chorea, or imbalance. SARA score was 3/40 [16]
and UPDRS motor score was 3/108. Anxiety was noticed
and neuropsychological tests showed mild executive dys-
function with mild disturbances of initiation, planification
flexibility and encoding episodic memory. Brain CT scan
revealed bilateral, symmetrical calcifications of lenticular
and caudate nuclei, thalami, cerebellar hemispheres and
vermis as well as mild sub-cortical and cortical calcifica-
tions (TCS = 46/80) (Fig. 1) [1]. Brain scintigraphy with
123I-Ioflupane showed marked, bilateral and symmetrical
dopaminergic neuron loss (Fig. 2) with a mean specific
striatum uptake of 2.3 (right) and 2.2 (left) (normal values
[3.5) whereas the putamen/caudate uptake ratio was 0.72
(right) and 0.71 (left) (normal values [0.85). A new
examination at age 42 revealed no particular change
although the patient felt better following speech and writ-
ing therapy.
In a complementation assay, we found that WT XPR1
fully complemented phosphate export inhibited by a
siRNA directed against XPR1 30UTR and that the L87P-
Fig. 1 Reduced pedigree of the patient carrying the novel p.(Leu87-
Pro) XPR1 variant. Filled symbols represent patients carrying brain
calcification and the grey circle represents the paternal aunt with a
history of parkinsonism but no CT scan
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mutated XPR1 did not (Fig. 3a), despite efficient expres-
sion, at the expected size of 82Kda albeit at a slightly lower
level than WT XPR1 (Fig. 3b). However, the mutant was
not detected at the cell surface, as monitored by flow
cytometry with XRBD, the XPR1 ligand (Fig. 3c), while
phosphate uptake and cell surface expression of the PiT1
and PiT2 phosphate importers remained unchanged
(Supplementary Figure). Decreased phosphate export was
also observed in PBMC obtained from the L87P PFBC
patient (Fig. 3d).
Discussion
This is the first report of an XPR1 pathogenic variant in a
PFBC patient since our primary report [7], confirming that
XPR1 is involved in the genetic determinism of PFBC and
may be responsible for parkinsonism. XPR1 mutations are
scarce since within the group of 65 patients negatively
screened for SLC20A2, PDGFB, and PDGFRB, including
the 18 patients reported here and the 47 patients previously
reported with the same inclusion criteria [7], 4 different
XPR1 pathogenic variants (i.e. class 5 following ACMG
recommendations [17]) in 5 families were found (7.7 %,
namely p.Ser136Asn, p.Leu140Pro, p.Leu145Pro, and
p.Leu218Ser). Two other rare missense variants
(p.Lys53Arg and p.Ile575Val) were detected in the primary
report but were predicted benign or tolerated by SIFT and
Polyphen2 programs with probably no effect on XPR1
function, as already shown for the p.Lys53Arg variant [7].
These two variants are therefore considered as likely non-
pathogenic (class 2 variants).
Although global correlation between calcification
severity and symptomatic status has been observed in case
series [1, 3, 18], no individual correlation could be inferred,
as illustrated by the apparent severity of the calcifications
on CT scan in our patient and the absence of marked dis-
ability even after 10 years of disease duration. In the same
way, parkinsonism was mild whereas the loss of
dopaminergic neurons was marked. Of note, although rel-
atives could not be examined and DNA was not available,
clinical presentation was quite homogeneous in this family
since all experienced parkinsonism and that, according to
the patient, his clinical picture was comparable to his
father’s. Brain calcification involved both lenticular, cau-
date nuclei, thalami, cerebellar hemispheres as well as
vermis and the depth of one cortical sulcus, as observed in
several but not all XPR1 mutation carriers [7]. In PFBC,
calcification leads to the diffuse involvement of the brain
which causes potential combination of numerous unspecific
signs including, beside parkinsonism, cerebellar ataxia,
executive dysfunction and anxiety such as in our case, and,
in other cases, dystonia, chorea, various psychiatric dis-
turbances, pyramidal signs, seizures or migraine.
Herein, we showed that the L87P variant causes dra-
matic drop of both XPR1 cell surface expression and
phosphate export, similar to what we previously reported in
other patients harboring the p.(Leu145Pro) variant [7]. As
L87P, all previously reported pathogenic variants
(c.407G[A, p.(Ser136Asn); c.420T[C, p.(Leu140Pro);
Fig. 2 Brain imaging of the patient carrying the novel p.(Leu87Pro)
XPR1 variant. Calcifications appear hyperdense on CT scan (a, b,
c) and hypointense on T2*-weighted MRI (d, e). They affect both
cerebellar hemispheres (a, d, full arrows), the vermis (a, dotted
arrow), the caudate nuclei (b, e, full arrows), the lenticular nuclei (b,
e, dotted arrows), the thalami (thin arrows), cerebral white matter
(not shown) and the cortex in the depth of one sulcus (c). On FLAIR-
weighted images, white matter hyperintensities are observed in
periventricular regions and posterior cerebral white matter (f).
123Ioflupane scintigraphy axial slides (g, h): marked, bilateral loss
of nigro-striatal dopaminergic neurons with left predominance
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and c.434T[C, p.(Leu145Pro) in exon 4, and
c.653T[C, p.(Leu218Ser) in exon 6) map to the SPX
domain [7], whose exact role is not yet understood [10, 19].
We found that deletion of SPX in WT XPR1 does not alter
phosphate export [10]. This and the facts that XPR1
mutations found in PFBC altered XPR1-mediated phos-
phate efflux, including two mutations that altered presence
of XPR1 at the cell surface (L87P and p.(Leu145Pro) [7]),
suggests that SPX plays a regulatory role and that muta-
tions are likely to alter interactions with factors involved in
cell surface trafficking and phosphate export. XPR1
mutations found in PFBC that altered phosphate export
could be distinguished as forms that were not expressed at
the cell surface, p.(Leu145Pro) [7] and L87P, and forms
that could be efficiently detected at the cell surface.
However, no obvious clinical difference could be noted
between these two groups of patients, or with the carriers of
SLC20A2, PDGFB, or PDGFRB variants [3, 7].
PFBC-associated SLC20A2 and XPR1 genes encode
phosphate importer and exporter, respectively. The mech-
anisms underlying brain calcification with molecules
transporting phosphate in opposite directions remains
hypothetical. Two recent studies showed that mice with
Slc20a2 haploinsufficiency presented high phosphate level
in CSF, predisposing to vascular brain calcification [20,
21]. Therefore, it is tempting to propose that PiT2 and
XPR1 participate in phosphate directional transport from
CSF to the blood in epithelial cells of the choroid plexus or
ependyma, known for regulating ion concentrations in
CSF. Finally, our study demonstrates that XPR1 mutations
are a scarce cause of PFBC and may be responsible for
parkinsonism.
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Fig. 3 Effect of the L87P mutation on XPR1 expression and
phosphate efflux. a Efflux of inorganic 33P (Pi) assay performed in
HEK293T cells transfected either with siRNA directed against
luciferase (siLUC), or anti XPR1 siRNA (siXPR1), or siXPR1 and
either an expression vector coding for HA-tagged WT XPR1 (XPR1-
HA) or the L87P mutant (L87P-HA) human XPR1. Results are shown
as mean ± SEM in a representative experiment (n = 3);
***P B 0.001, ****P B 0.0001, in comparison to the control
(siLUC). b Immunoblot of HA-tagged XPR1-containing cell lysates
probed with an anti-HA antibody (upper panel), or with an anti b-
actin antibody, used as loading control (lower panel). c Cell surface
detection of XPR1 with the X-MLV Env receptor-binding domain
(open histograms), in HEK293T transfected cells as in a and b. Non-
specific staining with the secondary IgG antibody alone is shown
(grey histograms). Numbers indicate the specific mean fluorescence
intensity of a representative experiment (n = 3). d Efflux of inorganic
33P (Pi) assay in PBMC isolated either from a healthy donor (circles)
or from a PFBC patient carrying the p.(Leu87Pro) alteration
(squares). Bars represent SEM ***P B 0.001
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